Introduction
============

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females worldwide, with an estimated 1.67 million new cases and 521,900 deaths in 2012. In developing countries, breast cancer incidence and mortality are rising, which have exceeded developed countries [@B1]. Metastasis is considered as a lethal step in the progression of breast cancer. Several risk factors have been identified to be related to breast cancer metastasis, such as tumor size, nodal status, histological grade, vascular invasion, etc. In addition, the expression of estrogen receptor (ER) and progesterone receptor (PR) and the amplification of HER2/c-erbB2 are closely linked with breast cancer metastasis, which provides the guidance to the adjuvant therapy for breast cancer [@B2]. Other molecules, such as miR-185-5p [@B3], cadherin-5 [@B4], Ku86 [@B5], and transforming growth factor β (TGF-β), are also associated with breast cancer metastasis. In addition, epithelial-to-mesenchymal transition (EMT) [@B6]-[@B8], circulating tumor cells [@B9], and the tumor microenvironment [@B10], [@B11] also contribute to the metastatic spread of breast cancer. While how these molecules and/or processes contribute to breast cancer metastasis is still not clearly understood, none of these has a definite prognostic value as a biomarker in breast cancer patients.

In recent years, innovations in high-throughput proteomic profiling approaches have allowed for highly sensitive, accurate, and quantitative identification of altered proteins in multiple samples at the same time. Isobaric tags for relative and absolute quantitation (iTRAQ) has been used successfully for the characterization of protein bioindicators of diverse effects [@B12]. Our goal in this study is to explore the differentially expressed proteins in matched primary breast tumor and metastatic lymph node tissue samples by the iTRAQ technique coupled with LC-MS/MS, aiming to identify reliable biomarkers for the prediction of breast cancer metastasis and prognosis.

Materials and Methods
=====================

Study subjects and clinical data
--------------------------------

A total of 23 paired female fresh primary breast tumor and metastatic lymph node tissues were collected and used for iTRAQ followed by LC-MS/MS. All of these patients were diagnosed as breast cancer and received surgeries without any pre-operative chemotherapy or radiotherapy in Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine of Center South University from January to May, 2014. Histological type was confirmed by two pathologists in the Department of Pathology of Hunan Cancer Hospital. Each tissue sample was divided into two parts, one part used for routine pathological examination and the other stored in liquid nitrogen for iTRAQ analysis.

In addition, 106 paraffin-embedded tissue samples for immunohistochemistry were obtained from female patients with metastatic breast cancer who had received surgeries in Hunan Cancer Hospital between 1996 and 2008. These were paired primary breast tumors and lymph node metastases (*n* = 106). All of these patients had no pre-operative chemotherapy or radiotherapy and the pathological parameters of the patients together with patients without lymph node metastasis (*n* = 83) were summarized in**Table [1](#T1){ref-type="table"}**. This study was approved by the Research Ethics Committee of Hunan Cancer Hospital, China and informed consent was obtained from all of the patients. The experiments performed in this study comply with the current laws of China relating to the use of human subjects.

iTRAQ proteomics
----------------

The iTRAQ kit was purchased from AB Sciex (USA) and proteomic analysis performed essentially as described in the manufacturer\'s instructions. The prepared lysates were treated with 4 µl reducing reagent for 1 h at 60°C and then blocked by 2 µl Cysteine blocking reagent for 10 min at room temperature. After centrifugation, the supernatant was collected and incubated with trypsin and tetraethylammonium bromide (TEAB) overnight at 37°C. The next day, the prepared sample and iTRAQ reagents were mixed together. Afterwards, two-dimensional LC-MS/MS was used to analyze the labeled samples and Proteinpilot 4.0 (AB Sciex) protein retrieval software was used to retrieve the separated peptides. This process was repeated for three times and the average was accepted as the final results. A greater than 1.5-fold change in expression was considered different between the primary breast tumor tissue and the paired metastatic lymph node tissue. This research was assisted by the FitGene BioTechnology proteomics platform (<http://www.fitgene.com>).

Immunohistochemistry
--------------------

Paraffin sections were baked in oven at 60°C for 2 h, and then dewaxed in two changes of xylene for 10 min each, followed by hydration in graded ethanol for 5 min each. For antigen retrieval, the slides were immerged into citric acid retrieval solution and heated in a microwave and cooled down at room temperature. Endogenous peroxidase activity was quenched by 3% H~2~O~2~ for 15 min. After blocking of nonspecific binding, the sections were incubated with the NUCB2 antibody (1:200, Abcam, UK) at 4°C overnight. Next, the sections were incubated with biotinylated secondary antibody followed by incubation with the streptavidin-peroxidase conjugate and color development using the DAB/H~2~O~2~ system. A negative control was included by replacing the primary antibody with PBS.

The immunostaining was evaluated by two independent experienced pathologists. The results of the two reviewers were compared and any discrepant scores were re-examined by both pathologists to reach a consensus score. A total immunostaining score (TIS) was calculated as the product of a proportion score and an intensity score. The proportion score described the estimated fraction of positive-stained tumor cells (0: 0-4%; 1: 5-25%; 2: 26-50%; 3: 51-75%; 4: \>75%). The intensity score represented the estimated staining intensity (0: no or marginal staining; 1: weak; 2: moderate; 3: strong). The TIS ranged from 0 to 12. We defined 0 as negative, 1-4 as weak positive, 5-8 as moderate positive, and 9-12 as strong positive.

Statistical analysis
--------------------

The difference of NUCB2 expression between paired primary breast tumor and metastatic lymph node was analyzed with McNemar test. In addition, the difference of NUCB2 expression between every other two different groups of patients with breast disease was evaluated with χ^2^ test. The relationship between NUCB2 expression and clinicopathologic characteristics was examined with χ^2^test. The survival rate was calculated with the Kaplan-Meier method and examined with log-rank test. Multivariate Cox hazard analysis was used to analyze the role of NUCB2 in breast cancer prognosis.

Results
=======

Differentially expressed proteins between primary breast tumor and metastatic lymph node tissues
------------------------------------------------------------------------------------------------

We first employed the iTRAQ technique to explore the differentially expressed proteins between 23 paired primary breast tumor and metastatic lymph node tissues. 4,837 confidential proteins were identified with a confidence interval (CI) ≥ 95%. Among these, 643 were differently expressed proteins, including 402 up-regulated and 241 down-regulated proteins in metastatic lymph nodes compared with the primary breast tumors. Gene ontology (GO) analysis revealed that the up-regulated proteins could be divided into 39 functional groups. The top ten up-regulated functional groups included RNA binding (29%), ion binding (27%), DNA binding (10%), enzyme binding (7%), structural constituent of ribosome (6%), ligase activity (5%), oxide reductase activity (5%), enzyme regulator activity (4%), protein binding transcriptional activity (4%), and kinase activity (3%) (**Figure [1](#F1){ref-type="fig"}A**). The down-regulated proteins could be divided into 31 functional groups. The top ten down-regulated functional groups included ion binding (36%), cytoskeletal protein binding (10%), enzyme binding (9%), structural molecular activity (9%), lipid binding (8%), enzyme regulator activity (8%), peptidase activity (7%), RNA binding (5%), oxide reductase activity (5%), and signal transducer activity (3%) (**Figure [1](#F1){ref-type="fig"}B**). The proteins up-regulated in the metastatic lymph nodes compared with the primary breast tumors were summarized in **Table [2](#T2){ref-type="table"}**.

NUCB2 is differentially expressed in lymph node metastasis in breast cancer
---------------------------------------------------------------------------

The expression of NUCB2, which is one of the most up-regulated proteins associated with DNA binding, was 1.92-fold higher in metastatic lymph node tissues than primary breast tumor tissues. According to GO analysis, NUCB2 is located in various compartments of the cell and its molecular functions include ion binding and DNA binding (<http://www.uniprot.org/uniprot/P80303>). The basic biological information about NUCB2 was summarized in **Table [3](#T3){ref-type="table"}**.

We further examined the expression of NUCB2 in primary breast tumors and paired metastatic lymph node tissues. NUCB2 staining was found predominantly in the cytoplasm of breast epithelial cells. The majority of the tissues examined showed weak staining of NUCB2 (TIS ≤ 4). NUCB2 expression was lower in metastatic lymph node than primary breast tumor tissues (*P*\< 0.001). (**Figure [2](#F2){ref-type="fig"}**). The positive expression rate of NUCB2 was 82.1% (87/106) in primary breast tumors and 47.2% (50/106) in metastatic lymph nodes, respectively. The expression of NUCB2 in primary breast tumors and metastatic lymph nodes was summarized in **Table [4](#T4){ref-type="table"}**. The results show that NUCB2 expression was down-regulated in metastatic lymph node tissues compared with primary breast tumors.

Correlation between NUCB2 expression and clinicopathological parameters
-----------------------------------------------------------------------

The correlation between NUCB2 expression and the clinicopathological parameters of breast cancer patients was analyzed by χ^2^. NUCB2 expression in breast tumors was significantly correlated with the extent of nodal invasion (*P*= 0.000), poor clinical stage (*P*= 0.001), and ER positivity (*P*= 0.020) (**Table [5](#T5){ref-type="table"}**). On the other hand, no association was found between positive expression of NUCB2 and age, histological type, histological grade, tumor size, PR, HER2/c-erbB-2, menstrual history, or modus operandi. Kaplan-Meier analysis revealed that the overall survival time of patients with positive NUCB2 expression was significantly shorter than those with negative NUCB2 expression (*P*= 0.004, **Figure [3](#F3){ref-type="fig"}**). In addition, Cox regression analysis showed that among all the risk factors examined, only high expression of NUCB2 (*P*= 0.025, RR = 2.065) was a risk factor for short overall survival of breast cancer patients (**Table [6](#T6){ref-type="table"}**). This means that high positive expression of NUCB2 is indeed associated with short overall survival time of breast cancer patients. Meanwhile, positive expression of NUCB2 in primary breast tumor is an independent risk factor for poor prognosis of breast cancer patients regardless of age, histological type, histological grade, nodal status, tumor size, clinical stage, ER, PR, HER2/c-erb-B2, menstrual history, and modus operandi.

Discussion
==========

Approximately 10-15% of patients with breast cancer have an aggressive disease and develop distant metastases within 3 years after the initial detection of the primary tumor. As it is not possible to accurately predict the risk of metastasis development in individual patients, 80% of the patients received adjuvant chemotherapy, among which 40% relapse and ultimately die of metastatic breast cancer [@B2]. Thus, we need to identify effective biomarkers or establish metastatic models to predict the occurrence of breast cancer metastasis to provide a better treatment for these patients. At present, many researches are focused on the different proteins of the primary tumor between breast cancer patients with or without lymph node metastases [@B13], or exploring the different proteins between cell lines with different metastatic potential [@B14]-[@B17]. However, no comparison has been made between the primary site and the metastatic site in patients with metastatic breast cancer.

In the present study, we employed the iTRAQ proteomic technique to screen the differentially expressed proteins between primary breast tumor and metastatic lymph node tissues. The initial search identified 4,837 confidential proteins and 643 differentially expressed proteins. Compared with primary breast tumors, 402 proteins were up-regulated and 241 proteins down-regulated in metastatic lymph nodes. The majority of these proteins are associated with RNA/DNA binding, enzyme binding and cytoskeleton protein binding, etc. These proteins are involved in lamellipodia formation [@B18], [@B19], angiogenesis [@B20], [@B21], circulating tumor cells [@B22], EMT [@B23], and tumor microenvironment [@B24] and may affect cell motility [@B25], cell proliferation [@B26], [@B27], invasion, migration, and metastasis [@B28], [@B29]. At the same time, several inflammatory factors were identified, such as complement C1r and complement component C8 gamma chain (C8G) etc. This might be an indication of a complex background including inflammatory response in the development of breast cancer metastasis [@B30], [@B31].

NUCB2 is a calcium-binding protein composed of 396 aa residues with a 24-aa signal peptide [@B23]. The human NUCB2 gene spans 55 kb and contains 14 exons and 13 introns [@B32]. It is highly conserved across mammalian and non-mammalian vertebrates, suggesting its physiological importance [@B33]. It is ubiquitously expressed in normal tissues, such as lymphoid tissue, pancreas, gut, and adipose [@B34], [@B35]. NUCB2 appears to play an important role in regulating energy homeostasis and food intake [@B36]. Adipose tissue plays important role in energy homeostasis and NUCB2 protein expression was significantly increased in high-fat-fed mice [@B37]. Li *et al.* reported that in high fat diet induced obese mice, gastric mTOR signaling and NUCB2 were increased [@B38]. Moreover, the activity of gastric mTOR is linked to the regulation of gastric NUCB2. A relation between obesity and ovarian cancer mortality was established and the N-terminal fragment of NUCB2 can inhibit the proliferation of human ovarian epithelial carcinoma HO-8910 cells through inducing apoptosis via the mTOR and RhoA/ROCK signaling pathway [@B39].

In addition, NUCB2 was also reported to be related to the development and progression of renal clear cell carcinoma [@B40] and prostate cancer [@B41]-[@B43]. In breast cancer, it has a positive association with lymph node metastasis and the ER status of the patients. Results of siRNA transfection experiments showed that NUCB2 was involved in cell proliferation, migration, and invasion in both ER-positive MCF-7 and ER-negative SK-BR-3 cells [@B44]. In our study, we analyzed the correlation between NUCB2 expression and clinicopathological features in 189 breast cancer patients. We demonstrated that NUCB2 has a significant positive correlation with the extent of nodal invasion, poorly clinical stage, and ER positivity. Obesity causes an increase in local estrogen production, which has a close correlation with breast cancer [@B45]. Suzuki *et al.* [@B23] demonstrated that NUCB2 was up-regulated by estrogen and our study showed that there was a positive correlation between NUCB2 expression and the ER status. Moreover, we found that breast cancer patients with high NUCB2 expression had a significantly poorer overall survival. Cox hazard regression analysis showed that NUCB2 expression and clinical stage were associated with overall survival of breast cancer. All these observations suggest that NUCB2 plays an important role in breast cancer progression and may be a potential prognostic biomarker for poor survival of breast cancer patients. Compared with the recently described serum biomarkers for breast cancer metastasis such as Y-box binding protein 1 (YB-1) [@B46] and HER2 [@B47], the immunohistochemical biomarker NUCB2 offers the advantages of increased sensitivity and higher specificity, because immunohistochemistry can reveal a biomarker change at an earlier stage and in a more specific location than a serum biomarker.

In summary, several differentially expressed proteins involved in breast cancer metastasis were identified by iTRAQ. NUCB2 was one of the highest expressed proteins in the paired primary breast tumors and metastatic lymph nodes and showed positive correlation with poor survival of breast cancer patients. NUCB2 has the potential to be used as an effective and novel biomarker for the prognostic prediction of breast cancer.
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![**Functional groups of differentially expressed proteins between the primary breast tumors and metastatic lymph nodes determined by GO analysis.** The top ten functional groups of proteins up-regulated (A) or down-regulated (B) in metastatic lymph nodes compared with primary breast tumors are shown.](jcav08p3062g001){#F1}

![**Expression of NUCB2 protein in primary breast tumors and metastatic lymph node tissues.**The paraffin-embedded tissue sections were immunohistochemically stained for NUCB2 expression and statistically evaluated by the χ^2^test. (A) Representative immunohistochemical images showing the predominantly cytoplasmic staining of NUCB2 in breast tumor samples. Original magnification: 200×. (B) Summary of the positive expression rate of NUCB2 in breast tumor samples. PBT, primary breast tumor; MLN, metastatic lymph node.](jcav08p3062g002){#F2}

![**Kaplan-Meier survival curves of patients with positive and negative NUCB2 expression.**The overall survival rate of breast cancer patients that were positive or negative for NUCB2 expression was calculated with the Kaplan-Meier method and examined with log-rank test. There was significant difference between the two groups (log-rank *P* = 0.004).](jcav08p3062g003){#F3}

###### 

Clinicopathological characteristics of breast cancer patients

  Parameters                                                  Numbers
  ----------------------------------------------------------- ------------
  **Median age (years, range)**                               45 (30-73)
  **Median follow up period for survivors (months, range)**   80 (8-210)
  **Histological type, n (%)**                                
  Ductal                                                      154 (81.5)
  Lobular                                                     35 (18.5)
  **Histological grade, n (%)**                               
  I & II                                                      33 (17.5)
  III                                                         156 (82.5)
  **Nodal status, n (%)**                                     
  Negative                                                    83 (43.9)
  Positive                                                    106 (56.1)
  **Tumor size (d, cm), n (%)**                               
  d ≤ 2                                                       56 (29.6)
  2 \< d ≤ 5                                                  112 (59.3)
  d \> 5                                                      20 (10.6)
  Unknown                                                     1 (0.5)
  **Clinical stage, n (%)**                                   
  I                                                           29 (15.3)
  II                                                          100 (52.9)
  III                                                         59 (31.2)
  Unknown                                                     1 (0.5)
  **ER, n (%)**                                               
  Negative                                                    90 (47.6)
  Positive                                                    99 (52.4)
  **PR, n (%)**                                               
  Negative                                                    78 (41.3)
  Positive                                                    111 (58.7)
  **C-erbB-2, n (%)**                                         
  Negative                                                    57 (30.2)
  Positive                                                    122 (64.6)
  Unknown                                                     10 (5.3)
  **Menstrual history, n (%)**                                
  Premenopause                                                123 (65.1)
  Postmenopause                                               66 (34.9)
  **Modus operandi, n (%)**                                   
  Radical mastectomy                                          82 (43.4)
  Modified radical mastectomy                                 100 (52.9)
  Other type                                                  7 (3.7)

###### 

Up-regulated proteins in metastatic lymph nodes compared to primary tumors

  Protein name                                                           Accession number            Sequence coverage (%)   Molecular weight   Isoelectric point   Ratio
  ---------------------------------------------------------------------- --------------------------- ----------------------- ------------------ ------------------- -------
  Transcriptional repressor protein YY1                                  sp\|P25490\|TYY1_HUMAN      20.05                   44,713             6.22                2.31
  Golgin subfamily B member 1                                            sp\|Q14789\|GOGB1_HUMAN     38.45                   376,019            4.66                1.93
  Dual specificity protein phosphatase 23                                sp\|Q9BVJ7\|DUS23_HUMAN     63.33                   16,588             8.15                1.93
  U1 small nuclear ribonucleoprotein C                                   sp\|P09234\|RU1C_HUMAN      30.19                   17,394             10.14               1.92
  Ribosome biogenesis protein BRX1 homolog                               sp\|Q8TDN6\|BRX1_HUMAN      28.05                   41,401             10.60               1.92
  Pescadillo homolog                                                     tr\|B3KXD6\|B3KXD6_HUMAN    50.33                   51,464             4.87                1.92
  WD repeat-containing protein 70                                        tr\|D6RIW8\|D6RIW8_HUMAN    27.39                   43,240             4.69                1.92
  Translocation protein SEC62                                            sp\|Q99442\|SEC62_HUMAN     31.58                   45,862             7.09                1.92
  28S ribosomal protein S23, mitochondrial                               sp\|Q9Y3D9\|RT23_HUMAN      56.84                   21,771             9.28                1.92
  **Nucleobindin-2**                                                     sp\|P80303\|NUCB2_HUMAN     46.9                    50,196             4.78                1.92
  Complement component 1 Q subcomponent-binding protein, mitochondrial   sp\|Q07021\|C1QBP_HUMAN     57.45                   31,362             4.47                1.92
  WD40 repeat-containing protein SMU1                                    sp\|Q2TAY7\|SMU1_HUMAN      31.77                   57,544             7.15                1.92
  Chromatin target of PRMT1 protein                                      sp\|Q9Y3Y2\|CHTOP_HUMAN     67.74                   26,397             12.74               1.91
  Copper chaperone for superoxide dismutase                              tr\|J3KNF4\|J3KNF4_HUMAN    38.43                   27,086             5.76                1.91
  Isoform 2 of Treacle protein                                           sp\|Q13428-2\|TCOF_HUMAN    27.85                   144,314            9.78                1.91
  Eukaryotic translation initiation factor 5B                            sp\|O60841\|IF2P_HUMAN      35.98                   138,827            5.15                1.89
  DDRGK domain-containing protein 1                                      sp\|Q96HY6\|DDRGK_HUMAN     50.32                   35,611             4.81                1.89
  28S ribosomal protein S22, mitochondrial                               sp\|P82650\|RT22_HUMAN      47.49                   41,280             7.85                1.89
  CAP-Gly domain-containing linker protein 1                             tr\|J3KP58\|J3KP58_HUMAN    38.75                   148,129            4.99                1.89
  SAFB-like transcription modulator                                      sp\|Q9NWH9\|SLTM_HUMAN      31.24                   117,148            7.93                1.89
  Pentatricopeptide repeat domain-containing protein 3, mitochondrial    sp\|Q96EY7\|PTCD3_HUMAN     25.54                   78,550             6.37                1.88
  Ubiquitin-like modifier-activating enzyme 1                            sp\|P22314\|UBA1_HUMAN      57.94                   117,849            5.50                1.88
  Isoform 3 of UPF0696 protein C11orf68                                  sp\|Q9H3H3-3\|CK068_HUMAN   46.08                   31,517             6.25                1.88
  Small nuclear ribonucleoprotein F                                      sp\|P62306\|RUXF_HUMAN      66.28                   9,725              4.34                1.87
  Isoform 3 of Cullin-4B                                                 sp\|Q13620-3\|CUL4B_HUMAN   41.84                   84,017             6.74                1.87
  Epithelial cell adhesion molecule                                      sp\|P16422\|EPCAM_HUMAN     41.72                   34,932             7.40                1.85
  26S protease regulatory subunit 8                                      sp\|P62195\|PRS8_HUMAN      81.77                   45,626             7.48                1.78
  Protein S100-A8                                                        sp\|P05109\|S10A8_HUMAN     67.74                   10,835             6.98                1.72
  Isoform B of Nucleoporin SEH1                                          sp\|Q96EE3-1\|SEH1_HUMAN    45.84                   46,578             7.87                1.68
  FAS-associated death domain protein                                    sp\|Q13158\|FADD_HUMAN      45.19                   23,279             5.40                1.51

###### 

Basic biological information about NUCB2

  Name                             Access number           Molecular weight   Isoelectric point   Cellular compartment   Molecular function
  -------------------------------- ----------------------- ------------------ ------------------- ---------------------- --------------------
  Nucleobinding-2                  sp\|P80303\|NUCB2-HUM   50,196             4.80                Nucleus                Ion binding
  Cytoplasm                        DNA binding                                                                           
  Cytosol                                                                                                                
  Extracellular region                                                                                                   
  Plasma membrane                                                                                                        
  Golgi apparatus                                                                                                        
  Endoplasmic reticulum                                                                                                  
  Nuclear envelope                                                                                                       
  Extracellular space (secreted)                                                                                         

###### 

Expression of NUCB2 in primary breast tumors and metastatic lymph nodes

        NUCB2 expression                           
  ----- ------------------ ------ ---- ------ ---- ------
  PBT   19                 17.9   73   68.9   14   13.2
  MLN   56                 52.8   47   44.3   3    2.8

TIS, total immunostaining score; PBT, primary breast tumor; MLN, metastatic lymph node.

###### 

Relationship between NUCB2 expression and clinicopathological parameters in breast cancer patients

  Characteristics                No. of patients   NUCB2 expression   *P* value\*   
  ------------------------------ ----------------- ------------------ ------------- -------
  **Age at diagnosis (years)**                                                      0.304
  \< 50                          112               40                 72            
  ≥50                            77                22                 55            
  **Histological type**                                                             0.555
  Ductal                         154               52                 102           
  Lobular                        35                10                 25            
  **Histological grade**                                                            0.632
  I- II                          33                12                 21            
  III                            156               50                 106           
  **Nodal status**                                                                  0.000
  Negative                       83                43                 40            
  Positive                       106               19                 87            
  **Tumor size (d, cm)**                                                            0.277
  d ≤ 2                          56                22                 34            
  2 \< d ≤ 5                     112               36                 76            
  d \> 5                         20                4                  16            
  Unknown \#                     1                                                  
  **Clinical stage**                                                                0.001
  I                              29                15                 14            
  II                             100               38                 62            
  III                            59                9                  50            
  Unknown \#                     1                                                  
  **ER**                                                                            0.020
  Negative                       90                37                 53            
  Positive                       99                25                 74            
  **PR**                                                                            0.165
  Negative                       78                30                 48            
  Positive                       111               32                 79            
  **C-erbB-2**                                                                      0.095
  Negative                       57                23                 34            
  Positive                       122               34                 88            
  Unknown \#                     10                                                 
  **Menstrual history**                                                             0.592
  Premenopause                   123               42                 81            
  Postmenopause                  66                20                 46            
  **Modus operandi**                                                                0.442
  Radical mastectomy             82                29                 53            
  Modified radical mastectomy    100               30                 70            
  Other type \#                  7                                                  

\* χ^2^test.

\# Unknown and other type cases are excluded from *P*-value calculation.

###### 

Cox regression analysis of risk factors for short overall survival time of breast cancer patients

  Variables               B         SE        Wald      Sig.        Exp (B) (95% CI)
  ----------------------- --------- --------- --------- ----------- -----------------------
  Age                     -0. 005   0\. 020   0\. 066   0\. 797     0\. 995 (0.956-1.035)
  Histological type       0\. 423   0\. 298   2\. 017   0\. 156     1\. 526 (0.852-2.735)
  Histological grade      0\. 654   0\. 450   2\. 056   0\. 152     1\. 906 (0.789-4.602)
  Nodal status            0\. 338   0\. 269   1\. 575   0\. 209     1\. 402 (0.827-2.375)
  Tumor size              0\. 093   0\. 235   0\. 156   0\. 693     1\. 097 (0.692-1.738)
  Clinical stage          0\. 140   0\. 413   0\. 115   0\. 734     1\. 151 (0.512-2.587)
  Estrogen Receptor       -0. 218   0\. 334   0\. 428   0\. 513     0\. 804 (0.418-1.546)
  Progesterone Receptor   -0. 430   0\. 342   1\. 579   0\. 209     0\. 651 (0.333-1.272)
  C-erbB-2                -0. 70    0\. 279   0\. 062   0\. 803     0\. 933 (0.540-1.612)
  Menstrual history       0\. 153   0\. 406   0\. 141   0\. 707     1\. 165 (0.526-2.581)
  Modus operandi          0\. 281   0\. 203   1\. 921   0\. 166     1\. 324 (0.890-1.969)
  NUCB2 expression        0\. 725   0\. 323   5\. 027   0\. 025\*   2\. 065 (1.096-3.891)

95% CI: 95% confidence interval

\**P* \< 0.05
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